Shopping Cart
Evidence-based overview
PRP Inhalation and PRP Nebulizers: What Does the Research Show?
Nebulized PRP or platelet lysate is being investigated as an experimental approach for respiratory disease. The evidence, however, is far more limited than some commercial claims and online reports suggest.
Experimental procedurePRP and platelet lysate are not the same
Publications on inhaled platelet products sometimes use PRP, activated PRP and platelet lysate imprecisely. The distinction matters because composition, cellular content and biological properties differ.
PRP
Platelet-Rich Plasma (PRP)
Plasma with a platelet concentration above baseline blood levels. Depending on the preparation method, it may contain leukocytes, residual red cells, anticoagulants and intact platelets.
PL
Platelet Lysate (PL)
A lysate derived from platelets. Platelets are activated or disrupted so that soluble components are released. The final preparation may be largely cell-free.
ImportantThe frequently cited laboratory paper mainly examined nebulized platelet lysate, not routine inhalation of unprocessed PRP in patients.
Why is inhaled delivery being studied?
Platelets are involved in more than clotting. They store signaling molecules and proteins that can influence inflammation, vascular responses and tissue repair. This has led to the hypothesis that platelet-derived preparations might be delivered locally through the airways to injured lung tissue.
The biology is not universally “regenerative.” Depending on the disease, preparation and tissue environment, platelet mediators may also contribute to inflammatory or fibrotic processes. In one mouse model, platelet depletion reduced fibrosis. This does not prove that PRP is harmful, but it shows why simple healing claims are not scientifically defensible.
Questions that nebulization must answer
- What droplet size is produced, and how much reaches the deeper lung?
- Do proteins and other components remain stable during aerosol generation?
- Are intact platelets activated, damaged or retained in the device?
- How are sterility, dose and reproducible composition secured?
What do the available studies show?
Level of evidence: very lowLaboratory study of platelet lysate
Material from four healthy donors was aerosolized with a compressor nebulizer. Analyzed molecules and biological activity in cell culture remained detectable. This was a feasibility experiment, not a patient trial.
Small study in smoke inhalation injury
A prospective study of 40 ventilated burn patients compared standard care with or without adjunctive nebulized autologous PRP. More favorable clinical outcomes were reported in the PRP group. The study was small, single-center and limited to a specific acute injury.
Post-COVID trial terminated early
A randomized double-blind trial planned to enroll 40 people with symptoms after COVID-19 ARDS. It was terminated for low recruitment after enrolling one participant. No results were posted.
2026 case report
Radiologic improvement was reported in a patient with persistent post-infective lung consolidation after nebulized autologous PRP. Without a control group, causation cannot be established. Pulmonary function testing and systematic clinical endpoints were absent.
Do not present as established indications
For which lung diseases is efficacy established?
Reliable efficacy has not been demonstrated for any of the commonly mentioned respiratory conditions. This includes COPD, emphysema, asthma, pulmonary fibrosis, acute COVID-19, long COVID, pneumonia and chronic bronchitis. Hypotheses, laboratory experiments and case reports are not substitutes for controlled clinical trials.
- COPD and emphysema
- Bronchial asthma
- Pulmonary fibrosis
- Long COVID and post-COVID syndrome
- Pneumonia and chronic bronchitis
Unresolved safety and quality issues
“Autologous” does not automatically mean risk-free. Delivery into the lower respiratory tract would require especially strict controls.
1
Preparation
Platelet concentration, leukocyte content, activation, anticoagulant and residual cells must be defined.
2
Microbiology
Manufacture, processing, storage and administration must reliably prevent contamination.
3
Device
A standard nebulizer is not automatically suitable for blood products or protein-rich biologics.
4
Tolerance
Cough, irritation, bronchospasm and possible inflammatory reactions require systematic study.
5
Dose
Volume, concentration, frequency, treatment duration and deposited dose are not standardized.
6
Monitoring
Experimental use requires a clinical protocol, consent, stopping rules and documented follow-up.
Not a self-treatment procedure
PRP or platelet lysate should not be prepared independently and placed in a standard inhaler or nebulizer. Beyond the lack of efficacy evidence, there are substantial risks from contamination, unsuitable devices, uncertain dosing and uncontrolled airway reactions.
A research concept, not an established lung therapy
Local airway delivery of platelet-derived preparations is scientifically interesting. Early laboratory work demonstrates technical feasibility, while small clinical observations provide only preliminary signals. Larger randomized studies, standardized products, validated nebulization protocols and systematic safety data are still required.
Medical noticePRP inhalation and nebulized platelet lysate are experimental procedures and are not established standard treatments for respiratory disease. This article is for professional information and does not provide a treatment recommendation.
Scientific sources
- Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific RationaleLaboratory/feasibility study; not a clinical efficacy trial.
- The Efficacy of Autologous Nebulized Platelet Rich Plasma (PRP) in the Management of Inhalation Lung InjurySmall prospective study in smoke inhalation injury.
- Nebulized PL for Post-COVID-19 Syndrome – NCT04487691Registered trial; terminated, actual enrollment: 1, no results posted.
- Case Report: Nebulized platelet-rich plasma facilitates resolution of post-infective pulmonary consolidation and cavitationSingle case report; temporal association without proof of causality.
- A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycinAnimal data illustrating the complex role of platelets in fibrosis.